C4X Discovery Holdings PLC Acquisition of drug-discovery technologies (8753D)
July 12 2016 - 2:00AM
UK Regulatory
TIDMC4XD
RNS Number : 8753D
C4X Discovery Holdings PLC
12 July 2016
This announcement contains inside information
C4X Discovery Holdings plc
("C4XD" or the "Company")
Acquisition of drug-discovery technologies from MolPlex Ltd
Proprietary platform technology further augments C4X Discovery's
drug discovery engine
12 July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an
innovative drug discovery and development company, today announces
the acquisition of a suite of advanced drug-discovery technologies
from MolPlex Ltd (the "Molplex Technologies").
The MolPlex Technologies comprise a pioneering software-based
system that combines state-of-the art chemoinformatics,
computational chemistry and artificial intelligence to optimize the
drug development process.
Currently, C4XD has the only technology in the world
(Conformetrix) that can use experimentally-determined
solution-structures to design drug molecules that are optimally
shaped to provide potency and selectivity. The MolPlex Technologies
will complement this by enabling C4XD to not only generate the
chemical starting point for such design programmes in rapid time,
but to also predict whether the resulting molecules have the
'druggable' qualities required for human administration (e.g.
absorption, solubility and metabolic stability), thereby reducing
the cost, time and attrition associated with early development and
increasing the likelihood of eventual clinical success.
The MolPlex Technologies were originally developed at Newcastle
University and have three aspects:
-- a vast in silico library of compounds that can be used for
virtual screening to provide quick chemical starting points for new
development programmes;
-- a molecular simulations system that enables medicinal
chemists to understand the interactions between drugs and their
targets;
-- algorithms that can predict the physiochemical properties of
lead molecules (such as absorption, distribution, metabolism,
excretion, cell permeability, solubility and plasma-protein
binding), enabling rapid optimisation of candidates for clinical
testing.
Dr Clive Dix, CEO of C4X Discovery, said: "These new
technologies, which we have brought into the business on very
economical terms, complement our existing platform and add to our
ability to capitalise on the identification of high-value targets
from our Taxonomy3(R) technology to generate drug candidates with
greater clinical and commercial differentiation. We are rapidly
building an internal pipeline of exciting therapeutic programmes
and moving steadily towards realising our goal of becoming the
world's most productive drug discovery and development
company."
C4XD acquired the technologies from MolPlex Ltd, which is
currently in administration, for a non-material amount.
--ENDS--
For further information please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865803
Zeus Capital Limited
Dan Bate
0161 393 1973
Dominic Wilson/Phil Walker
0203 829 5000
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal, Melissa Gardiner
0203 709 5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery and development company by exploiting cutting-edge
technologies to design and create best-in-class drug candidates.
The Company has two proprietary and synergistic software platforms
"Taxonomy3(R)" and "Conformetrix" that provide a significant
competitive advantage when combined with an experienced management
team. "Taxonomy3(R)" is a human genetics analysis platform that
utilises a unique mathematical approach to discovery and validation
of drug targets for the treatment of a variety of diseases.
"Conformetrix" determines the 3D shape of drug molecules from
experimental in vitro data that enables the rapid design and
discovery of novel and potent drugs for diseases with high unmet
medical need across broad therapeutic areas. We have a hybrid
business model of wholly-owned programmes and partnerships with
pharma, biotech and academics.
The Company was founded in 2008 as a spin-out from the
University of Manchester and has a highly experienced management
team and Board who have delivered significant value creation within
the healthcare sector historically. For additional information
please go to: www.c4xdiscovery.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFFLLFQDFZBBE
(END) Dow Jones Newswires
July 12, 2016 02:00 ET (06:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024